Serum obestatin and omentin levels in patients with diabetic nephropathy
Date
2017-02-01Author
CELIK, K.KISKAC, MUHARREM
ZORLU, MEHMET
KOCYIGIT, ABDÜRRAHİM
YAVUZ, E.
Gueler, ERAY METİN
GUELTEPE, I.
Advisor
Type
Metadata
Show full item recordAbstract
Introduction: Diabetic nephropathy is the leading cause of chronic kidney disease and accounts for almost 45% of
all new patients requiring renal replacement therapy. Omentin and obestatin, two novel proteins were suggested to be
associated with insulin resistance, type 2 diabetes and cardiovascular risk factors. Thus, we postulated that they may
also have an association with diabetic nephropathy which is known to be an independent cardiovascular risk factor. In
order to investigate such an association we compared serum omentin and obestatin levels in type 2 diabetic patients
with normoalbuminuria (NA) and macroalbuminuria (MA).
Materials and Methods: A total of 81 type 2 diabetic patients were separated into two groups according to their
proteinuria status; patients with NA (n = 39) and patients with MA (n = 42). Two groups were compared in terms of
serum omentin and obestatin levels.
Results: While serum omentin levels did not differ among two groups (P = 0.407), serum obestatin levels were
significantly higher in MA group (P = 0.001).
Conclusion: The results of this study showed that higher serum levels of obestatin were associated with macro
albuminuria suggesting that obestatin may have a role in underlying pathogenic mechanisms that leads to diabetic
nephropathy
Collections
- Tıp Fakültesi [2546]
- Yayınlar - Eserler [10056]